aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Rheonix, Inc., based in Ithaca, United States, is a biomedical device company focused on miniaturizing and automating assays across various fields. Their flagship product, the CARD (Chemistry And Reagent Device) system, supports applications in human and veterinary diagnostics, food and water testing, SNP analysis for personalized medicine, homeland security, process control, and tissue culture analysis. Rheonix aims to provide accessible and efficient molecular testing solutions.
Rheonix has achieved significant milestones, including the development of the Encompass family of workstations, which offers fully automated and integrated molecular testing with meaningful multiplexing capabilities. Their collaboration with the FDA/CFSAN on Cyclospora cayetanensis data underscores their impact on public health. Rheonix's products are designed to be open and adaptable, enabling laboratories to develop customized assays and streamline their testing processes.
Operating Status
Active
Ownership Type(s)
Private
Main Product(s)
Biomedical Devices
Technology
Automation
Tags
Biotech, Data
Model Types
Hardware, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise, Government
Geographic Exposure
United States
When was Rheonix founded?
Rheonix was founded in 2007.
Where is Rheonix’s headquarters located?
Rheonix’s headquarters is located in Ithaca, NY, US.
How many employees does Rheonix have?
Rheonix has 67 employees as of Feb 5, 2024.
How much has Rheonix raised to-date?
As of July 05, 2023, Rheonix has raised a total of $86.7M (USD) since Feb 13, 2019.
Add Comparison
Total Raised to Date
$86.7M
USD
Last Update Feb 13, 2019
Total Employees Over Time
67
As of Feb 2024
Rheonix Address
10 Brown Rd
Ithaca,
New York
14850-1287
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts